文献速递妇科

来曲唑联合安罗替尼作为无化疗方案用于二线铂类化疗失败后的ER阳性铂耐药复发性上皮性卵巢癌患者:一项前瞻性、单臂、开放标签、II期研究

Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study.
PubMed 文献 · Gynecol Oncol · 2025-10-29

这项单臂II期研究评估来曲唑联合安罗替尼治疗二线铂类化疗失败后的ER阳性铂耐药复发性上皮性卵巢癌患者,27例入组,客观缓解率为25.9%(95%CI 11.8%-46.6%),疾病控制率为74.1%(95%CI 53.4%-88.1%),中位无进展生存期为4.57个月(95%CI 4.07-9.66),多数不良事件为1-2级且可控。

要点

  • 来曲唑联合安罗替尼在ER阳性铂耐药复发性上皮性卵巢癌中客观缓解率为25.9%(95%CI 11.8%-46.6%)。
  • 疾病控制率为74.1%(95%CI 53.4%-88.1%),中位无进展生存期为4.57个月(95%CI 4.07-9.66)。
  • 多数不良事件为1-2级且可控,原发铂间隔超过6个月、基线CA-125低于500 IU或ER表达≥25%者显示统计学显著的治疗获益。

核心结论

  • 来曲唑联合安罗替尼在二线铂类化疗失败后的ER阳性铂耐药复发性上皮性卵巢癌患者中显示出有前景的疗效和可控的毒性。

研究设计与样本

  • 单臂II期研究(NCT04720807),2021年1月至2023年12月评估30例患者资格,入组27例。
  • 患者接受口服安罗替尼10 mg每日一次(第1-14天,每21天为一周期)和持续口服来曲唑2.5 mg,直至疾病进展、死亡、不可耐受毒性或患者退出。
  • 主要终点为根据RECIST 1.1版和GCIG标准的客观缓解率。

主要发现

  • 中位年龄62岁(范围50-79)。
  • 7例患者达到部分缓解,无患者达到完全缓解,客观缓解率为25.9%(95%CI 11.8%-46.6%)。
  • 疾病控制率为74.1%(95%CI 53.4%-88.1%)。
  • 中位无进展生存期为4.57个月(95%CI 4.07-9.66)。
  • 原发铂间隔超过6个月、基线CA-125水平低于500 IU或ER表达水平较高(≥25%染色阳性)的患者显示出统计学显著的治疗获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Estrogen receptor-positive (ER-positive) platinum-resistant recurrent epithelial ovarian cancer (PROC) patients following second-line platinum-based chemotherapy failure face the dilemma of limited therapeutic options. We aimed to evaluate the efficacy and safety of letrozole plus anlotinib for these patients. METHODS: We conducted a single-arm phase 2 study (NCT04720807) evaluating letrozole plus anlotinib in ER-positive PROC patients following second-line platinum-based chemotherapy failure. Patients received oral anlotinib 10 mg daily (days 1-14, q21d) and continuous oral letrozole 2.5 mg. Treatment was continued until disease progression, death, intolerant toxicity, or patient withdrawal. The primary endpoint was the objective response rate (ORR) according to RECIST version 1·1 and the GCIG criteria. RESULTS: Between January 2021 and December 2023, 30 patients were assessed for eligibility, and 27 patients were enrolled. The median age was 62 years (range 50-79). Seven patients achieved a partial response, while no patients showed a complete response, resulting in an ORR of 25·9 % (95 % CI, 11·8 %-46·6 %). The disease control rate was 74·1 % (95 % CI, 53·4 %-88·1 %). The median progression-free survival was 4·57 months (95 % CI, 4·07-9·66). Most adverse events were Grade 1-2 and manageable. Patients with a primary platinum-free interval exceeding 6 months, lower baseline CA-125 levels (<500 IU), or higher ER expression levels (≥ 25 % stained positive for ER) showed a statistically significant treatment benefit. CONCLUSION: The combination of letrozole plus anlotinib demonstrated promising efficacy and manageable toxicity in the treatment of ER-positive PROC patients following second-line platinum-based chemotherapy failure.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Li J, Yang Y, et al. Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study. Gynecol Oncol. 2025. PMID: 41166983. doi:10.1016/j.ygyno.2025.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。